Our venture capital fund focuses investments on early-stage life sciences companies looking to improve people’s outcomes with cancer.

Recent News

aiProteins_Final_logo300
05/31/2023

AI Proteins Announces the Formation of a Scientific Advisory Board Made up of Experts in Biotech and FDA Drug Approval

READ MORE
C4-logo-400
05/30/2023

C4 Therapeutics and Betta Pharmaceuticals Announce Exclusive Licensing Agreement for the Development and Commercialization in Greater China of CFT8919, an Orally Bioavailable BiDAC™ Degrader of EGFR L858R for NSCLC

READ MORE
SimpleRose-logo
05/22/2023

St. Louis high-potential tech startup emerges from stealth mode

READ MORE
aiProteins_Final_logo300
05/18/2023

AI Proteins Expands Leadership Team with Two Key Hires

READ MORE
wugen-logo-400
05/11/2023

Wugen Announces Multiple Presentations at the European Hematology Association (EHA) 2023 Congress

READ MORE
wugen-logo-400
05/10/2023

Wugen Appoints Industry Leader Mark Alles as Chair of the Board of Directors

READ MORE
C4-logo-400
05/04/2023

C4 Therapeutics Reports First Quarter 2023 Financial Results and Recent Business Highlights

READ MORE
wugen-logo-400
04/19/2023

Wugen Presents New Preclinical Data Reinforcing Anti-Tumor Functionality of WU-NK-101 at the American Association for Cancer Research (AACR) Annual Meeting 2023

READ MORE
C4-logo-400
04/19/2023

C4 Therapeutics to Participate in the Stifel 2023 Virtual Targeted Oncology Days

READ MORE

PORTFOLIO HIGHLIGHTS

WUGEN Logo
White C4 Therapeutics logo
Geneoscopy logo
NextRNA Logo
CareVet Logo
microbial-logo-header300